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To determine antimicrobial drug resistance patterns, 
we characterized nontyphoidal Salmonella enterica strains 
isolated in Liverpool, UK, January 2003 through December 
2009. Decreased susceptibility to ciprofl oxacin was found 
in 103 (20.9%) of 492 isolates. The lower susceptibility was 
associated with ciprofl oxacin treatment failures and with 
particular serovars and phage types often acquired during 
foreign travel. 
Nontyphoidal Salmonella enterica (NTS) isolates pro-duce a common food-related infection that causes 
mild and self-limiting diarrhea and, occasionally, a poten-
tially fatal invasive disease with bacteremia and endovas-
cular infection (1). Antimicrobial drug therapy, often with 
the fl uoroquinolone ciprofl oxacin, is required for treating 
invasive NTS infections and severe diarrhea in immuno-
compromised patients. Full resistance to fl uoroquinolones 
is relatively uncommon for NTS infections, but decreased 
susceptibility to ciprofl oxacin (DCS), defi ned as MIC 
0.1–1.0 μg/mL, has become common (2). Resistance to 
nalidixic acid is often used as a marker for DCS, although 
the validity of this assumption has been debated (3), and 
some have suggested that the ciprofl oxacin disk suscepti-
bility zone size breakpoints should be changed to detect 
such strains (2).
DCS is associated with ciprofl oxacin treatment fail-
ures in patients with typhoid fever (4) and probably with 
invasive NTS infection, although the clinical signifi cance 
of DCS in NTS has not been widely explored (5–7). Clini-
cal clues to the presence of DCS in S. enterica infections 
could guide early empirical prescription of antimicrobial 
drug therapy. Links between DCS and foreign travel have 
been suggested in reports from Denmark (8) and Finland 
(9,10). In this study, we characterized the resistance pat-
terns of NTS strains isolated in Liverpool and explored 
the value of nalidixic acid–resistance testing, the clinical 
signifi cance of DCS, and possible links between DCS and 
foreign travel. 
The Study
We studied all isolates of NTS detected in samples 
submitted to the microbiology department at the Royal 
Liverpool University Hospital from patients in the Mersey-
side area from January 2003 through December 2009. Iso-
lates were identifi ed by standard biochemical and serologic 
methods. Disk susceptibility testing was performed for am-
picillin, trimethoprim, ciprofl oxacin, and ceftriaxone. Na-
lidixic acid testing was recommended but not consistently 
performed. The serovar, phage type, and susceptibility of 
each isolate were confi rmed by the Laboratory for Gas-
trointestinal Pathogens, Health Protection Agency Centre 
for Infections, Colindale, London. Isolates were stored in 
glycerol broth at −70°C and later subcultured for determi-
nation of MICs to ciprofl oxacin and nalidixic acid by using 
the agar dilution and the Etest strip methods. The control 
organisms Escherichia coli ATCC 25922 and Staphylococ-
cus aureus ATCC 25923 were used. Breakpoints were de-
fi ned according to Clinical Laboratory Standards Institute 
guidelines (11). DCS was defi ned as MIC 0.1–1.0 μg/mL 
and resistance MIC >1 μg/mL.
Laboratory data, including serovar and antimicro-
bial drug susceptibility patterns, were merged with statu-
tory notifi cation of diseases data from the Cheshire and 
Merseyside Health Protection Unit of the Health Protec-
tion Agency. This second database contained the travel 
history (validated through an enhanced questionnaire) of 
the patients, detailing whether they had a relevant history 
of foreign travel and, if so, where they had traveled. The 
medical records of patients with bacteremia were retrieved 
and reviewed to establish whether ciprofl oxacin had been 
used for therapy and the clinical outcome.
A total of 492 unique NTS patient isolates, including 
isolates from 116 inpatients, were identifi ed during the 
study period. Diarrheal isolates accounted for 479 of the 
total; 11 were from blood, 1 was from a wrist aspirate, and 
1 was from a pathology specimen of the large bowel. The 
number and proportion of isolates resistant to ampicillin 
were 39 (7.9%), to trimethoprim 22 (4.5%), to ciprofl oxacin 
2 (0.4%), and to ceftriaxone 6 (1.2%). Resistance to na-
lidixic acid was determined at isolation for 281 (57.1%) 
of 492 isolates and was found for 53 (18.9%). When all 
492 patient isolates were tested, 103 (20.9%) were resis-
tant to nalidixic acid, including both isolates that were cip-
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rofl oxacin resistant. Of 397 (81%) isolates retrievable for 
MIC testing, all 304 with a MIC of ciprofl oxacin <0.1 μg/
mL were also susceptible to nalidixic acid, 91 had DCS 
(0.1–1.0 μg/mL), all but 1 were resistant to nalidixic acid, 
and 2 were resistant to nalidixic acid and ciprofl oxacin with 
a ciprofl oxacin MIC >4.0 μg/mL. Nalidixic acid resistance 
correlated well with DCS.
Forty-eight named serovars of S. enterica were found 
among the 492 characterized isolates. The serovars most 
commonly isolated from patients with nalidixic acid re-
sistance were Enteritidis phage type 1 (PT1), Virchow, 
Newport, and Enteritidis PT21; the fi rst 3 of these were 
also commonly associated with a history of foreign travel 
(Table). The higher levels of DCS in serovars Enteritidis 
and Virchow and lower levels in serovar Typhimurium are 
consistent with data from Europe, as is the association with 
particular serovar Enteritidis phage types (12,13).
A relevant foreign travel history was reported for 110 
(22.4%) of 492 patients; destinations were identifi able 
for 105, including 36 countries from across Asia, Europe, 
South America, and Africa. Countries most commonly im-
plicated were Spain (22; 20.0%), Egypt (11; 10.0%), Tur-
key (10; 9.1%), India (8; 7.3%), and Thailand (5; 4.6%). 
Among the 110 isolates from patients who had traveled, 
35 (31.8%) were resistant to nalidixic acid compared with 
68 (17.8%) from the 382 patients with no history of for-
eign travel (odds ratio [OR] 2.15, 95% confi dence interval 
[CI] 1.30–3.57; p<0.001). Travel to Egypt (OR 5.3, 95% CI 
1.59–17.99; p = 0.007), Spain (OR 3.08, CI 1.27–7.48; p = 
0.018), and Thailand (OR 17.51, CI 2.8–109.33; p = 0.002) 
was associated with DCS; these countries were also identi-
fi ed in other studies (8–10). High levels of DCS or resis-
tance to ciprofl oxacin have been observed among isolates 
of NTS from Spain and Thailand (14,15). This study does 
not include rates of travel to various destinations, so the 
higher numbers of S. enterica isolates with DCS in travel-
ers to some destinations may simply refl ect travel patterns.
In a multivariate analysis, after different serovars and 
phage types and history of foreign travel were adjusted for, 
DCS was independently associated with serovars Enter-
itidis PT1 (OR 14.42, CI 6.41–32.43; p<0.001), Enteritidis 
PT21 (OR 5.81, CI 2.1–16.08; p = 0.001), Newport (OR 
9.38, CI 2.8–31.38; p<0.001), and Virchow (OR 62.33, CI 
7.37–526.82; p<0.001) but not with a history of foreign 
travel (OR 1.54, CI 0.82–2.85; p = 0.178). This fi nding 
suggests that the association with particular serovars and 
phage types is greater than any association with foreign 
travel and that travel is a factor only because travel can 
facilitate importation of these serovars.
The clinical features of the 11 patients with bacteremia 
are summarized in the online Appendix Table (www.cdc.
gov/EID/content/17/1/123-appT.htm); 10 either were im-
munosuppressed or had gall bladder disease. Five blood 
culture isolates were resistant to nalidixic acid with DCS. 
Ciprofl oxacin was the initial drug choice for 3 of the pa-
tients infected with a DCS isolate, but in each instance, 
the drug was changed to an alternative (ceftriaxone for 
2 patients, ampicillin for 1) because of an unsatisfactory 
clinical response. The other 2 patients initially received a 
cephalosporin, and outcome was acceptable. Although ex-
tended-spectrum cephalosporins are the principal alterna-
tive antimicrobial drugs for treatment of bacteremic infec-
tions, resistance is also emerging (2,13). Six of the isolates 
in this study were resistant to ceftriaxone, including 1 of 
the isolates from a patient with bacteremia, which was sus-
ceptible to ciprofl oxacin.
Conclusions
Our data show that one fi fth of NTS isolates in Liv-
erpool demonstrated nalidixic acid resistance and that this 
was a good marker for DCS. The data also suggest that 
DCS may compromise ciprofl oxacin therapy for invasive 
disease caused by NTS. Infection with particular serovars 
and phage type, frequently associated with foreign travel, 
were signifi cant risk factors for infection with an S. enterica 
isolate with DCS, and this information can help guide ini-
tial empirical antimicrobial drug choices. Early detection 
of DCS is essential, but nalidixic acid–resistance testing 
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Table. Relationship between nontyphoidal Salmonella enterica serovar, phage type, nalidixic acid resistance, and history of foreign 
travel, Liverpool, UK, 2003–2009* 
Serovar
Total no. (%) 
patient isolates 
No. (%) patients with 
foreign travel history 
No. (%) patients with 
nalidixic acid–resistant 
isolate 
No. (%) patients with foreign 
travel history and nalidixic 
acid–resistant isolate 
All 492 (100.0) 110 (22.4) 103 (20.9) 35 (31.8) 
Enteritidis PT1 53 (10.8) 16 (30.2) 36 (67.9) 9 (56.3) 
Enteritidis PT4 93 (18.9) 12 (12.9) 4 (4.3) 2 (16.7) 
Enteritidis PT8 43 (8.7) 8 (18.6) 1 (2.3) 1 (12.5) 
Enteritidis PT21 22 (4.5) 5 (22.7) 10 (45.4) 1 (20.0) 
Enteritidis (other PT) 104 (21.1) 13 (12.5) 16 (15.4) 3 (23.1) 
Typhimurium 44 (8.9) 11 (25.0) 3 (6.8) 1 (9.1) 
Newport 14 (2.8) 3 (21.4) 8 (57.1) 3 (100.0) 
Virchow 12 (2.4) 9 (75.0) 11 (91.7) 8 (88.9) 
Other 107 (21.7) 33 (30.8) 14 (13.1) 7 (21.2) 
*PT, phage type. 
Ciprofl oxacin Susceptibility in Salmonella enterica
was not always performed at the time of isolation. Revision 
of ciprofl oxacin disk susceptibility breakpoints would al-
low such isolates to be detected more easily. 
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